Clinical Trial Update: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the immunogenicity and safety of the BPZE1 intranasal pertussis vaccine in healthy school-age children has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pertussis

Drugs mentioned

• BPZE1 Intranasal Pertussis Vaccine (BPZE1)

Snippet

Sponsor: ILiAD Biotechnologies | Conditions: Bordetella Pertussis, Whooping Cough | Phase 2 | Status: COMPLETED | Results posted: 2025-11-06